Evidence map›Paper›PMID 27655672›Full record

ArticleOncotarget2016

Positive association of collagen type I with non-muscle invasive bladder cancer progression.

Michael Brooks, Qianxing Mo, Ross Krasnow, Philip Levy Ho, Yu-Cheng Lee, Jing Xiao, Antonina Kurtova, Seth Lerner, Gui Godoy, Weiguo Jian and 5 more

Open access · diamondAbstract readMulticenter Study
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 79 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Michael BrooksScott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA.
Qianxing MoDepartment of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA.
Ross KrasnowScott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA.
Philip Levy HoDepartment of Urology, Baylor College of Medicine, Kelsey-Seybold Clinic, Houston, Texas 77030, USA.
Yu-Cheng LeeDepartment of Molecular & Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA.
Jing XiaoDepartment of Molecular & Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA.
Antonina KurtovaDepartment of Molecular & Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA.
Seth LernerScott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA.
Gui GodoyScott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA.
Weiguo JianScott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA.
Patricia CastroDepartment of Pathology and Immunology, and Michael E. DeBakey VAMC, Baylor College of Medicine, Houston, Texas 77030, USA.
Fengju ChenDepartment of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA.
David RowleyDepartment of Molecular & Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA.
Michael IttmannDepartment of Pathology and Immunology, and Michael E. DeBakey VAMC, Baylor College of Medicine, Houston, Texas 77030, USA.
Keith Syson ChanScott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA.
Baylor College of Medicine · US

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9M
Distinct Tumor and Metastatic Collagen Microenvironments: Divergent Targeting ApproachesR01CA175397 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHAN, KEITH SYSON · 2013 to 2025
$4.8M
NCI NIH HHS P30 CA125123NCI NIH HHS R01 CA175397
6 · The paper itself

Abstract

purposeNon-muscle invasive bladder cancers (NMIBC) are generally curable, while ~15% progresses into muscle-invasive cancer with poor prognosis. While efforts have been made to identify genetic alternations associated with progression, the extracellular matrix (ECM) microenvironment remains largely unexplored. Type I collagen is a major component of the bladder ECM, and can be altered during cancer progression. We set out to explore the association of type I collagen with NMIBC progression. EXPERIMENTAL

designThe associations of COL1A1 and COL1A2 mRNA levels with progression were evaluated in a multi-center cohort of 189 patients with NMIBCs. Type I collagen protein expression and structure were evaluated in an independent single-center cohort of 80 patients with NMIBCs. Immunohistochemical analysis was performed and state-of-the-art multi-photon microscopy was used to evaluate collagen structure via second harmonic generation imaging. Progression to muscle invasion was the primary outcome. Kaplan-Meier method, Cox regression, and Wilcoxon rank-sum were used for statistical analysis.

resultsThere is a significant association of high COL1A1 and COL1A2 mRNA expression in patients with poor progression-free survival (P=0.0037 and P=0.011, respectively) and overall survival (P=0.024 and P=0.012, respectively). Additionally, immunohistochemistry analysis of type I collagen protein deposition revealed a significant association with progression (P=0.0145); Second-harmonic generation imaging revealed a significant lower collagen fiber curvature ratio in patients with invasive progression (P = 0.0018).

conclusionsAlterations in the ECM microenvironment, particularly type I collagen, likely contributes to bladder cancer progression. These findings will open avenues to future functional studies to investigate ECM-tumor interaction as a potential therapeutic intervention to treat NMIBCs.

Indexed as

Tumor MicroenvironmentAgedBiomarkers, TumorCollagen Type ICollagen Type I, alpha 1 ChainDisease-Free SurvivalDisease ProgressionExtracellular MatrixFemaleHumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedNeoplasm InvasivenessOligonucleotide Array Sequence AnalysisBiomarkers, TumorCOL1A2 protein, humanCollagen Type ICollagen Type I, alpha 1 ChainRNA, Messengerbladder cancercancer progressioninvasiontumor microenvironmenttype I collagen

Identifiers

PMID27655672
PMCPMC5347718
OpenAlexW2519490965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.